Group 1 - Invea Therapeutics, a clinical-stage biotech company developing oral small molecule drugs for inflammatory diseases, withdrew its initial public offering (IPO) plan due to market conditions [1] - The company had previously filed a prospectus to issue 3.2 million shares at a price range of $10 to $12 per share, aiming to raise $35 million [1] - Founded in 2021 and headquartered in Guilford, Connecticut, Invea Therapeutics planned to list on NASDAQ under the ticker symbol INAI [1] Group 2 - ThinkEquity was set to be the exclusive book-running manager for the IPO transaction [1]

Core Viewpoint - Invea Therapeutics has withdrawn its initial public offering (IPO) plan due to market conditions, which was aimed at raising $35 million by offering 3.2 million shares at a price range of $10 to $12 per share [1] Company Overview - Invea Therapeutics is a clinical-stage biotechnology company focused on developing oral small molecule drugs for inflammatory diseases [1] - The company was founded in 2021 and is headquartered in Guilford, Connecticut [1] IPO Details - The company had planned to list on NASDAQ under the ticker symbol INAI [1] - ThinkEquity was set to be the exclusive bookrunner for the IPO [1]